The startup develops curative therapies that utilize novel, first-in-class biopharmaceutical candidates to treat complex diseases in oncology, autoimmune disorders, and pain management. By focusing on holistic patient care, the company aims to improve patient outcomes and extend life expectancy through its clinical-stage pipeline.
Funding
$170.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancers, especially hematological malignancies and solid tumors, remain difficult to treat effectively, leading to poor patient outcomes and reduced life expectancy. Current therapies often fail to fully eradicate the disease or are associated with significant toxicities, creating a need for more targeted and innovative treatment approaches.
Solution
Ichnos Glenmark Innovation (IGI) is a clinical-stage biotechnology company focused on developing a pipeline of novel biologics and small molecules for treating cancers. IGI leverages its proprietary BEAT® (Bispecific Engagement by Antibodies based on the T-cell receptor) platform to create multispecific antibodies that enhance the immune system's ability to target and kill cancer cells. The company's pipeline includes clinical-stage assets targeting multiple myeloma and preclinical candidates for solid tumors, employing diverse mechanisms of action such as T-cell and NK-cell engagers, as well as small molecule Cbl-b inhibitors.
Target Audience
IGI's therapies target patients with hematological malignancies, such as multiple myeloma, and solid tumors, as well as pharmaceutical companies seeking to in-license innovative oncology assets.
Features
- BEAT® platform for generating multispecific antibodies with optimized target affinity and avidity
- TREAT™ trispecific antibodies that redirect T lymphocytes to kill tumor cells expressing multiple antigens
- IMMUNITE™ NK-cell engagers designed to harness the power of natural killer cells against solid tumors
- Cbl-b inhibitor small molecule with demonstrated tumor growth inhibition and durable complete responses in preclinical studies
- Clinical-stage assets including ISB 2001 (BCMA x CD38 x CD3) and ISB 1442 (CD38 x CD47) in Phase 1 trials for multiple myeloma
- Dual binding to CD38 and CD47 epitopes, increasing avidity relative to daratumumab
- One arm blocks CD47-SIRPa binding on tumor cells to enhance ADCP
- Optimized tolerability with low potential for adverse effects on red blood cells such as hemagglutination, platelet aggregation